^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Poorly Differentiated Neuroendocrine Carcinoma/Large or Small Cell (Extrapulmonary): Locoregional Unresectable/Metastatic Disease:...Nivolumab + ipilimumab (category 2B) (only for metastatic disease with progression).
